1,622
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study

, , , , , , , , , & show all
Pages 793-801 | Received 19 Jan 2023, Accepted 07 Aug 2023, Published online: 07 Sep 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.